Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allantoin - Amicus Therapeutics

Next Previous
Drug Profile

Allantoin - Amicus Therapeutics

Alternative Names: SD-101 - Amicus Therapeutics; Zorblisa

Latest Information Update: 14 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Paradigm Therapeutics Inc; Scioderm
  • Developer Amicus Therapeutics; Scioderm
  • Class Anti-inflammatories; Antiacnes; Antipsoriatics; Hydantoins; Imidazolidines; Keratolytics; Small molecules; Urea compounds
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Epidermolysis bullosa
  • Discontinued Diabetic foot ulcer; Psoriasis

Most Recent Events

  • 06 May 2025 Development of allantoin for Epidermolysis bullosa is still ongoing in USA (Topical)
  • 06 May 2025 Paradigm Therapeutics plans to submit NDA in the US in the second half of 2025
  • 22 Aug 2023 Paradigm Therapeutics acquires allantoin from Amicus Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top